Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled trial of deuremidevir hydrobromide for suspension in hospitalized infants and young children with RSV infection
CTR20234163Phase 2Completed
- Sponsor
- Vigonvita Life Sciences
- Start
- Jan 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of deuremidevir in respiratory syncytial virus disease (RSV), sponsored by Vigonvita Life Sciences. Started Jan 2024; status: completed.
02
Drugs
deuremidevir
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on CTR20234163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234163.